Search

Author/Creator Smolin, Alexey

2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Issue 12 (December 2020)

Authors:
Powles, Thomas; van der Heijden, Michiel S; Castellano, Daniel; Galsky, Matthew D; Loriot, Yohann; Petrylak, Daniel P; Ogawa, Osamu; Park, Se Hoon; Lee, Jae-Lyun; De Giorgi, Ugo; Bögemann, Martin; Bamias, Aristotelis; Eigl, Bernhard J; Gurney, Howard; Mukherjee, Som D; Fradet, Yves; Skoneczna, Iw...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 12(2020)
Page Start:
1574
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Issue 10212 (23rd November 2019)

Authors:
Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowic...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1929
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Issue 1 (January 2021)

Authors:
Goldman, Jonathan W; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Garassino, Marina Chiara; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libo...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 1(2021)
Page Start:
51
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Issue 10212 (23rd November 2019)

Authors:
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro, Gilberto; Psyrri, Amanda; Basté, Neus; Neupane, Prakash; Bratland, Åse; Fuereder, Thorsten; Hughes, Brett G M; Mesía, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Wan Ishak, Wan Zamaniah; Hon...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1915
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗